Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Preventive Cardiology

stylized illustration of cholesterol particle floating in bloodstream

Novel siRNA Produces Deep, Durable Reduction in Lp(a)

Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability

converging lines on a graph pointing downward

Oxidized Phospholipids Track Closely With Lp(a) Reductions in Clinical Trial

Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran

sight picture overlaid on DNA double helix

Positive Effects of CRISPR-Cas9 Gene Editing for Dyslipidemia Endure Through 1 Year

Durability findings propel potential one-time treatment approach to phase 1b testing

illustrated platelets forming a clot in a blood vessel

Bempedoic Acid Appears to Curb VTE Risk in Statin-Intolerant Patients

Post hoc analysis of CLEAR Outcomes trial bolsters its case as a statin alternative

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

doctor taking pulse of a woman in an exam room

Counseling Patients on the New Cholesterol Guideline: What Providers Should Know

How to talk about lifetime risk, treatment goals, Lp(a) testing, statin skepticism and more

stylized scientific illustration of hormone receptors

Dual-Agonist Incretin Therapy Outshines GLP-1 Agonist in Broad Cardiorenal Outcomes

Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials

LDL cholesterol particle with a DNA double helix on top of it

CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia Shows Safety and Preliminary Efficacy

First-in-human phase 1 trial induced loss of function in gene that codes for ANGPTL3

LDL cholesterol particles floating in bloodstream

Obicetrapib-Ezetimibe Combo Therapy Halves LDL Cholesterol Levels Relative to Placebo

Phase 3 TANDEM study may help pave way to first approval of a CETP inhibitor

lipoprotein(a) particle

Large Cohort Study Reveals Vanishingly Small Rates of Lipoprotein(a) Testing

Yet 21.4% of tested individuals had Lp(a) elevation

Lp(a) particles floating among red blood cells

Lepodisiran’s Large, Durable Lp(a) Reductions in Phase 2 Trial Boost Anticipation of Phase 3 Results

Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose

BackPage 1 of 5Next

Advertisement

Ad